Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.

Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. Lancet Haematol. 2017 Apr; 4(4):e176-e182.

View in: PubMed

subject areas

Aged
Antineoplastic Agents
Antineoplastic Agents, Immunological
Antineoplastic Combined Chemotherapy Protocols
Drug Administration Schedule
Female
Humans
Lymphoma, Follicular
Lymphoma, Mantle-Cell
Male
Maximum Tolerated Dose
Middle Aged
Neoplasm Recurrence, Local
Purines
Quinazolinones
Rituximab
Thalidomide

authors with profiles

Sonali Smith